The role of angiogenic factors in endometrial cancer

Endometrial cancer

Endometrial cancer is one of the most common cancers in women in Poland and around the world. Every year about 190 thousand new cases of endometrial cancer and about 45 thousand deaths are registered. It is commonly believed that it is a tumor that occurs in highly developed and developing countries, and that it is closely related to the so-called “Western way of life” [1].
Endometrial cancer is the most common malignancy within the female reproductive system (37.7%) [2]. The incidence increases with age. Frequently this type of cancer is diagnosed in peri- and post-menopausal women. 60-70% of cancers occur in women over 60 years of age, and less than 5% in women below 40 years of age [1, 3].
Factors that increase the risk of developing endometrial cancer include early menarche, late menopause, age, obesity, diabetes, menstrual disorders, anovulatory cycles, polycystic ovary syndrome, childlessness, hormone replacement therapy (HRT), and estrogen-secreting tumors [4].
Malignant tumors of the uterus may vary according to histological structure. Most of the cells derive from the endometrium. 80% of endometrial cancers are adenocarcinomas. 60-65% of them are endometrioid cancers [1, 5, 6]. The remaining 20% of endometrial cancers are serous and clear cell adenocarcinomas. Mixed type of endometrial cancer represents about 10%. A rare form of endometrial cancer is mucinous adenocarcinoma – about 9% [5]. Other rare kinds of endometrial cancer include endometrioid cancer with squamous metaplasia, small cell neuroendocrine carcinoma, squamous cell carcinoma, transitional cell carcinoma, and sarcomas [1, 5].
Bokham, based on years of clinical observations of endometrial cancer, divided it into 2 types. Type 1 – the most common one – accounts for about 80% of diagnoses. These are mainly endometrial endometrioid carcinomas. These types of tumors are estrogen-dependent. They develop on the basis of hypertrophic endometrium. They are characterized by slow growth and a good prognosis. These types of tumors occur in both menopausal and pre-menopausal women. In endometrial endometrioid cancers, characteristic mutations in the PTEN gene, K-ras, and microsatellite instability inception occur. Type II – nonendometrioid – tumors are not estrogen-dependent, growing on the substrate atrophic endometrium. From the biological point of view, these tumors are very aggressive and have a poor prognosis. These tumors occur predominantly in women after menopause. In the cases of type II tumors, mutations in p53 and HER2/neu [7] occur.

Angiogenesis versus vasculogenesis

Neovascularization involves two processes – vasculogenesis and angiogenesis.
Vasculogenesis means formation of a vascular plexus by differentiation of hemangioblasts into endothelial cells without a pre-existing vascular system. The process of vasculogenesis occurs for example in the fetal life.
Angiogenesis is a process of formation of new microvessels from existing capillaries. Angiogenesis occurs in fetal life. In adults angiogenesis is a rare process, except for wound healing, menstrual cycle, and some diseases for example endometriosis, diabetic retinopathy, and rheumatoid arthritis [8]. Angiogenesis is necessary for the formation and development of all cancers. In 1971, Folkman pointed out the importance of angiogenesis for the development of cancer, which was a milestone in the field of cancer biology [9].
In the initial phase of cancer progression the tumor is a cluster consisting of about 1 million cells and does not exceed 2 mm3. At this stage of its growth and development it is independent from the vascular network. Nutrients and oxygen are transported to the tumor cells by diffusion. In the later stages of carcinogenesis, the tumor stimulates the production of new blood vessels, because the current supply becomes insufficient – in the central part of the tumor necrosis may occur. The newly formed vessels in the tumor are necessary, since they provide essential nutrients and oxygen to the tumor cells and allow continuous growth and unlimited proliferation. Simultaneously, the tumor vascular network is used to spread the cancer in the body – metastasis [9-12].
There are four different mechanisms of new vessels’ growth: sprouting, intussusception, vessel elongation and incorporation of endothelial progenitor cells into new microvessels. Sprouting is also called classic angiogenesis. It is associated with active endothelial cells, that produce proteases. Proteases break down the basement membrane, and allow endothelial cells to migrate toward the circulating angiogenic factors. New microvessels are stabilized by pericytes and smooth muscle cells. This process is controlled by angiopoietin-1, which binds to endothelial Tie-2 receptors [13, 14].
The second mechanism is intussusception, which consists in partitioning the lumen of the vessels into two separate vessels. Endothelial cells migrate inwards and create a network of new vessels [13]. Elongation is the mechanism most frequently occurring during organism growth.

Growth factors and angiogenesis

The newly formed vessels, with many additional features, are a source of growth factors, cytokines, and hormones that stimulate the development of the tumor [15]. They show proteolytic activity, which increases tumor invasiveness [16, 17]. Angiogenesis under physiological conditions is strictly regulated. In healthy subjects, the relationship between pro-angiogenic and anti-angiogenic factors points in the direction of the latter. In cancer, these processes are getting out of control. This leads to constant production of pro-angiogenic factors; at the same time activity of antiangiogenic factors and their expression are reduced – the “angiogenic switch” is turned on [8]. The fact that angiogenesis is closely associated with the development of cancer became the starting point for research on a new method of treatment in the fight against cancer – anti-angiogenic therapy. This idea already appeared in the year after the groundbreaking discovery by Folkman [18]. More than 30 years later, the first tumor angiogenesis inhibitory drug (Avastin/bevacizumab) was approved for clinical use [19, 20].

Vascular endothelial growth factor family

Vascular endothelial growth factor (VEGF) plays a crucial role in the initiation of physiological and pathological angiogenesis, lymphangiogenesis, and vasculogenesis. VEGF is the most powerful and most specific endothelial cell growth factor. VEGF synthesis is stimulated under conditions of hypoxia by hypoxia inducible factor (HIF). HIF binds with the promoter of the gene and stimulates its transcription [21].
VEGF was discovered in 1983 by Dvorak [22]. The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PLGF (placental growth factor) [23]. The effects of VEGF are mediated through binding to the two specific and homologous receptors VEGFR-1 (FLT-1) and VEGFR-2 (KDR). Other receptors by means of which VEGF works are VEGFR-3 and neuropilin 1 and 2, which are semaphorin receptors. Specific ligand-receptor interaction induces a different effect on endothelial cells. VEGF-A, VEGF-B and PLGF act through VEGFR-1 and are responsible for the formation of new vessels. VEGF-A, VEGF-B, VEGF-C and VEGF-D work through VEGFR-2 and are responsible for angiogenesis, proliferation and migration. VEGF-C and VEGF-D act through VEGFR-3 and are responsible for the processes of lymphangiogenesis, proliferation and migration [24-26].
The VEGF gene consists of 8 exons. During transcription 6 protein isoforms are formed: VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, VEGF206.
VEGF121, VEGF165, VEGF189 isoforms are most commonly produced by various cells types [27, 28].
Many factors that stimulate angiogenesis act indirectly through the induction of VEGF expression, for example transforming growth factor (TGF), endothelial growth factor (EGF), and platelet-derived growth factor (PDGF) [29, 30].

Placental growth factor

Placental growth factor belongs to the VEGF family. It was discovered in 1991 by Maria Graziella Perscio [31]. The human PLGF gene is located on 14 chromosome and consists of seven exons. The PLGF amino acid sequence is 42% identical with the sequence of VEGF and has significant structural similarity [32]. So far four isoforms of PLGF have been identified: PLGF-1 (PLGF131), PLGF-2 (PLGF152), PLGF-3 (PLGF203) and PLGF-4 (PLGF224). These four isoforms are the result of alternative splicing overlap [32, 33]. PLGF isoforms differ in terms of both their section properties and their binding affinities. PLGF-1 is a dimeric protein with a molecular mass of about 46 kDa. It is composed of 131 amino acids. PLGF-1 binds to VEGFR-1 and is predominantly expressed by vascular endothelial cells. PLGF-2 consists of 170 amino acid residues prior to signal peptide (18 amino acid residues in length) cleavage. A highly basic 21 amino acid insertion in the carboxy-terminal region of PLGF-2 results in high heparin binding affinity. PLGF-2 binds neuropilin 1 and 2, which are receptors for the semaphorin family of proteins. PLGF-3 contains an insertion of 216 nucleotides coding for a 72-amino acid sequence between exons 4 and 5 of the PLGF gene. PLGF-3 like PLGF-1 binds to VEGFR-1. PLGF-4 consists of the same sequence as PLGF-3. PLGF-4 like PLGF-2 has a heparin-binding domain [33-35].
PLGF is a positive regulator of angiogenesis. It can stimulate this process by several mechanisms, for example a direct impact on endothelial cells by VEGF-1, sensitization of cells to VEGF–VEGFR by the interaction of PLGF–VEGFR-1, separation of the VEGF from receptor-1, simultaneously enabling the binding of VEGF to VEGFR-2, mobilization of hematopoietic progenitor cells from bone marrow, and recruitment of monocytes/macrophages which are involved in the process of vessel growth [31, 36-38].
PLGF activity is not detectable in healthy organs. PLGF activity is highly unregulated in pathological conditions. PLGF was originally demonstrated in the placenta, but it is also present in heart, lungs, thyroid, muscles and adipose tissue [39, 40]. Placental growth factor levels correlate with poor prognosis of cancers, for example colorectal cancer, hepatocellular cancer or renal cancer [41, 42]. Many reports have suggested that PLGF might by a useful prognostic marker of cancer progression. Plasma PLGF levels correlate with tumor grade and survival in patients with renal cell carcinoma [43]. High preoperative PLGF serum level is a prognostic factor of recurrence and survival in patients with colorectal cancer [44]. Zhang et al. suggest that PLGF mRNA and protein in tumor cells are correlated with tumor stage in lung cancer [41]. Parr et al. came to similar conclusions in patients with breast cancer [45].
Circulating levels of PLGF are elevated not only in patients with different kinds of cancers but also in patients with atherosclerosis and ischemic heart disease. A high plasma level of PLGF in patients with acute coronary syndrome within 12 hours of the onset of symptoms is a poor prognostic factor [46, 47]. In the skin, PLGF expression is upregulated during wound healing [48].
PLGF may also act as an inhibitor of angiogenesis. That happens when PLGF creates a heterodimer with VEGF. This complex has from 20 to 50 times less stimulatory effect on angiogenesis as compared to VEGF homodimer [49, 50]. PLGF can block VEGF-stimulated angiogenesis by reducing the pool of VEGF homodimers [51].

Vascular endothelial growth factor and placental growth factor in endometrial cancer

Angiogenesis plays important roles not only in growth of endometrial cancers but also in the menstrual cycle. The endometrium is a very dynamic organ that constantly proliferates and breaks down. However, angiogenesis in uterine endometrial cancers is complicated because steroid hormone modifies the angiogenic potential in their growth.
VEGF-A/VEGFR-1 expression has been investigated as an angiogenic factor in benign and malignant diseases of uterine endometrium. It is involved in physiological angiogenesis in the menstrual cycle and in pathological angiogenesis. VEGF-A/VEGFR-1 expression is affected by exogenous hormone therapy [52-54]. Zhang et al. reported greater VEGF expression in the endometrial epithelium than in stromal cells. VEGF expression in greater in the secretory phase than in the proliferative phase [55].
Saito et al. studied the role of angiogenic factors in normal endometrium and endometrial adenocarcinoma. One of the examined angiogenic factors was VEGF. They proved that VEGF expression was recognized in all phases. It was higher in the functional layer of early and mid-secretory phases. In the basal layer VEGF was expressed in the mid to late secretory phases. In the G1 and G2 adenocarcinoma samples, VEGF expression was higher than in the proliferative phases of normal endometrium. VEGF expression in the endothelial cells was not correlated with the histological grade [56]. Fujimoto et al. reported that in normal endometrium and endometrial cancers mainly VEGF165 and VEGF121 and their mRNA were detected. VEGF protein and mRNA were expressed in normal uterine endometrium. Their levels were significantly higher in normal uterine endometrium than in endometrial cancers. VEGF protein and mRNA levels were inversely proportional to histological grade, myometrial invasion and clinical stages of endometrial cancer [57]. Giatromanolaki et al. found no association between VEGF expression and histological type and grade, depth of myometrial invasion or lymph vascular space invasion [58].
The role of PLGF in the development of endometrial cancer has not been thoroughly investigated. There are not many publications concerning this subject. The role of PLGF has been investigated in several cancer types, for example breast and colorectal cancer. For endometrial cancer the prognostic function of PLGF has to be investigated. Coenegrachts et al. conducted research on the role of PLGF in endometrial cancer, and the correlation between PLGF expression and histological and clinical data. They found that serum PLGF levels are increased only in late stages of cancer. Only in high-grade endometrial carcinomas is local PLGF expression increased. They did not observe any statistically significant correlation between serum PLGF levels and clinical stage of endometrial cancer. They reported that serum PLGF levels cannot be used as a prognostic or diagnostic marker of endometrial cancer [59].

Acknowledgements

Praca realizowana w ramach projektu badawczego finansowanego przez Uniwersytet Medyczny w Łodzi nr 502-03/5-105-02/502-54-128.

Disclosure

Authors report no conflicts of interest.

References

1. World Cancer Report. Steward BW, Kleihues P (eds.). IARC Press, Lyon 2003. Uterine cancer, pp. 217-219.
2. Gabryś MS. Epidemiologia i etiopatogeneza raka błony śluzowej trzonu macicy. In: Ginekologia onkologiczna. Tom 2. Markowska H (ed.). Urban & Partner, Wrocław 2006, pp. 683-685.
3. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide. IARC, Lyon 2008; http://globocan.iarc.fr/
4. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009; 16: 14-22.
5. Tumours of the uterine corpus. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA, Devilee P (eds.). IARC Press, Lyon 2003, pp. 217-257.
6. Urbański K, Kornafel J (eds.). Ginekologia onkologiczna. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Via Media, Gdańsk 2007. Część I. Onkologia w praktyce klinicznej 2007; 3 (suppl C): pp. 235-240.
7. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
8. Hanahan D, Folkamn J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
10. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
11. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50: 63-70.
12. Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040-1041.
13. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
14. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
15. Casper RF. Regulation of estrogen/progesterone receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41: 16-21.
16. Brooks PC, Strömblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
17. Skobe M, Rockwell P, Goldstein N, et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-1227.
18. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
19. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003; 361: 1959.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
21. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
22. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
23. Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550-563.
24. Stuttfeld E, Ballmer-Hofer K. Structure and functionof VEGF receptors. IUBMB Life 2009; 61: 915-922.
25. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69: 4-10.
26. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006; 96: 223-268.
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
28. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114 (Pt 5): 853-865.
29. Saharinen P, Tammela T, Karkkainen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25: 387-395.
30. Siegfried G, Basak A, Cromlish JA, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003; 111: 1723-1732.
31. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci 1991; 88: 9267-9271.
32. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8: 925-931.
33. Yang W, Ahn H, Hinrichs M, et al. Evidence of a novel isoform of placenta growth factor (PIGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 2003; 60: 53-60.
34. Autiero M, Waltenberger J, Communi D, et al. Role of PLGF in the intra- and intermolecular cross talk between the VEGF receptors Flt 1 and Flk 1. Nat Med 2003; 9: 936-943.
35. Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates collapsing-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsing-1 and vascular endothelial growth factor-165. J Cell Biol 1999; 146: 233-242.
36. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
37. Viita H, Markkanen J, Eriksson E, et al. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and down regulation of VEGF receptor 2 expression. Circ Res 2008; 102: 177-184.
38. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
39. Perscio MG, VincentiV, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PLGF). Curr Top Microbiol Immunol 1999; 237: 41-40.
40. Voros G, Maquoi E, Demeulemeester D, et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545-4554.
41. Zhang L, Chen J, Ke Y, et al. Expression of placenta growth factor (PLGF) in non small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005; 3: 68.
42. Wei SC, Tsao PN, Yu SC, et al. Placentha growth factor is correlated with survival of patients with colorectal cancer. Gut 2005; 54: 666-672.
43. Matsumoto K, Suzuki K, Kolke H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003; 23: 4953-4958.
44. Wei SC, Liang JT, Tsao PN, et al. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009; 52: 1630-1636.
45. Parr C, Watkins G, Boulton M, et al. Placenta growth factor in over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005; 41: 2819-2827.
46. Heeschen C, Dimmeler C, Fichtlscherer S, et al. Prognostic value of placenta growth factor in patients with acute chest pain. JAMA 2004; 291: 435-441.
47. Lendrink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 307-311.
48. Kagawa S, Matsumoto A, Yagi Y, et al. The time-course analysis of gene expression during wound healing in mouse skin. Leg Med 2009; 11: 70-75.
49. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996; 271: 3154-3162.
50. Schromber T, Kopfstein I, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 2007; 67: 10840-10848.
51. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006; 66: 3971-3977.
52. Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1995; 78: 454-460.
53. Smith SK. Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 1998; 4: 509-519.
54. Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999; 72: 220-231.
55. Zhang L, Scott PA, Turley H, et al. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the humanendometrium. J Pathol 1998; 185: 402-408.
56. Saito M, Sato Y, Watanabe J, et al. Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Pathol Int 2007; 50: 140-147.
57. Fujimoto J, Ichigo S, Hirose R, et al. Expression of vascular endothelial growth factor (VEGF) and it’s mRNA inuterine endometrial cancers. Cancer Lett 1998; 134: 15-22.
58. Giatromanolaki A, Siviridis E, Brekken R, et al. The angiogenic “Vascular endothelial growth factor/flk-1 (KDR) receptor” pathway in patients with endometrial carcinoma. Cancer 2001; 92: 2569-2577.
59. Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep 2013; 29: 413-418.